Literature DB >> 21822028

I-CLIP: improved stratification of advanced hepatocellular carcinoma patients by integrating plasma IGF-1 into CLIP score.

Ahmed O Kaseb1, James L Abbruzzese, Jean-Nicolas Vauthey, Thomas A Aloia, Eddie K Abdalla, Manal M Hassan, E Lin, Lianchun Xiao, Adel S El-Deeb, Asif Rashid, Jeffrey S Morris.   

Abstract

OBJECTIVE: Improving the prognostic stratification of unresectable hepatocellular carcinoma (HCC) patients is critically needed. Since patients' survival is closely linked to the severity of the underlying liver disease, and insulin-like growth factor-1 (IGF-1) is produced predominantly in the liver, we hypothesized that IGF-1 may correlate with patients' survival and hence improve the prognostic ability of the Cancer of the Liver Italian Program (CLIP) score.
METHODS: Baseline plasma IGF-1 and clinicopathologic parameters were available from 288 patients. Multivariate Cox regression models, Kaplan-Meier curves, and the log-rank test were applied. Recursive partitioning was used to determine the optimal cut point for IGF-1 using training/validation samples. Prognostic ability of the I-CLIP (I = IGF) was compared to CLIP using C-index.
RESULTS: IGF-1 significantly correlated with the clinicopathologic features. With an optimal IGF-1 cut point of 26 ng/ml, the overall survival of patients with IGF-1 >26 was 17.7 months (95% CI 13.6-22.8), and with IGF-1 ≤26 was 5.8 months (95% CI 4.0-12.5), p < 0.0001. The concordance probabilities for CLIP and I-CLIP were 0.7037 and 0.7096, respectively (p < 0.0001).
CONCLUSIONS: Our preliminary results indicate that I-CLIP significantly improved prognostic stratification of patients with advanced HCC. However, independent validation of our study is warranted.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21822028      PMCID: PMC3171278          DOI: 10.1159/000329040

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  31 in total

1.  Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

Authors:  Fidel-David Huitzil-Melendez; Marinela Capanu; Eileen M O'Reilly; Austin Duffy; Bolorsukh Gansukh; Leonard L Saltz; Ghassan K Abou-Alfa
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Possible contribution of serum activin A and IGF-1 in the development of hepatocellular carcinoma in Egyptian patients suffering from combined hepatitis C virus infection and hepatic schistosomiasis.

Authors:  Mohamed Yousry Elsammak; Gamal M Amin; Gehan M Khalil; Wafaa S Ragab; Mona M Abaza
Journal:  Clin Biochem       Date:  2006-04-19       Impact factor: 3.281

3.  Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma: one cross-sectional correlation study.

Authors:  Wei-Wen Su; King-Teh Lee; Yao-Tsung Yeh; Maw-Soan Soon; Chao-Ling Wang; Ming-Lung Yu; Shen-Nien Wang
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

4.  Expression of albumin, IGF-1, IGFBP-3 in tumor tissues and adjacent non-tumor tissues of hepatocellular carcinoma patients with cirrhosis.

Authors:  Shi-Min Luo; Wei-Min Tan; Wei-Xiong Deng; Si-Min Zhuang; Jian-Wei Luo
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

5.  Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience.

Authors:  Federica Mirici-Cappa; Annagiulia Gramenzi; Valentina Santi; Andrea Zambruni; Antonio Di Micoli; Marta Frigerio; Francesca Maraldi; Maria Anna Di Nolfo; Paolo Del Poggio; Luisa Benvegnù; Gianludovico Rapaccini; Fabio Farinati; Marco Zoli; Franco Borzio; Edoardo Giovanni Giannini; Eugenio Caturelli; Mauro Bernardi; Franco Trevisani
Journal:  Gut       Date:  2010-03       Impact factor: 23.059

6.  Selecting an optimal staging system for hepatocellular carcinoma: comparison of 5 currently used prognostic models.

Authors:  Chia-Yang Hsu; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Pui-Ching Lee; Che-Chuan Loong; Jen-Huey Chiang; Teh-Ia Huo; Shou-Dong Lee
Journal:  Cancer       Date:  2010-06-15       Impact factor: 6.860

7.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

8.  Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.

Authors:  C-H Hsu; T-S Yang; C Hsu; H C Toh; R J Epstein; L-T Hsiao; P-J Chen; Z-Z Lin; T-Y Chao; A-L Cheng
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

Review 9.  Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature.

Authors:  Ahmed O Kaseb; Amr Hanbali; Matthew Cotant; Manal M Hassan; Ira Wollner; Philip A Philip
Journal:  Cancer       Date:  2009-11-01       Impact factor: 6.860

10.  IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients.

Authors:  David García-Galiano; Miguel A Sánchez-Garrido; Isabel Espejo; José Luis Montero; Guadalupe Costán; Trinidad Marchal; Antonio Membrives; José M Gallardo-Valverde; Juan R Muñoz-Castañeda; Eugenio Arévalo; Manuel De la Mata; Jordi Muntané
Journal:  Obes Surg       Date:  2007-04       Impact factor: 4.129

View more
  19 in total

Review 1.  Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we?

Authors:  Yu-Yun Shao; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

Review 2.  Staging systems of hepatocellular carcinoma: a review of literature.

Authors:  Marcello Maida; Emanuele Orlando; Calogero Cammà; Giuseppe Cabibbo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  Reassessing hepatocellular carcinoma staging in a changing patient population.

Authors:  Ahmed O Kaseb; Neeraj N Shah; Hesham M Hassabo; Jeffrey S Morris; Lianchun Xiao; Yasmin M Abaza; Khalid Soliman; Ju-Seog Lee; Jean-Nicholas Vauthey; Michael Wallace; Thomas A Aloia; Steven Curley; James L Abbruzzese; Manal M Hassan
Journal:  Oncology       Date:  2014-01-08       Impact factor: 2.935

Review 4.  Diagnosis and treatment of hepatocellular carcinoma: An update.

Authors:  Javier Tejeda-Maldonado; Ignacio García-Juárez; Jonathan Aguirre-Valadez; Adrián González-Aguirre; Mario Vilatobá-Chapa; Alejandra Armengol-Alonso; Francisco Escobar-Penagos; Aldo Torre; Juan Francisco Sánchez-Ávila; Diego Luis Carrillo-Pérez
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

Review 6.  Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology.

Authors:  Jan Hansmann; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

7.  Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma.

Authors:  Ahmed O Kaseb; Jeffrey S Morris; Manal M Hassan; Adnan M Siddiqui; E Lin; Lianchun Xiao; Eddie K Abdalla; Jean-Nicolas Vauthey; Thomas A Aloia; Sunil Krishnan; James L Abbruzzese
Journal:  J Clin Oncol       Date:  2011-09-12       Impact factor: 44.544

8.  Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma.

Authors:  Jong Kwan Kim; Hyung-Don Kim; Mi-Jung Jun; Sung-Cheol Yun; Ju Hyun Shim; Han Chu Lee; Danbi Lee; Jihyun An; Young-Suk Lim; Young-Hwa Chung; Yung Sang Lee; Kang Mo Kim
Journal:  Dig Dis Sci       Date:  2017-08-16       Impact factor: 3.199

9.  Validation of a Preclinical Model of Diethylnitrosamine-Induced Hepatic Neoplasia in Yucatan Miniature Pigs.

Authors:  Jennifer Mitchell; Peggy T Tinkey; Rony Avritscher; Carolyn Van Pelt; Ghazaleh Eskandari; Suraj Konnath George; Lianchun Xiao; Erik Cressman; Jeffrey S Morris; Asif Rashid; Ahmed O Kaseb; Hesham M Amin; Rajesh Uthamanthil
Journal:  Oncology       Date:  2016-06-16       Impact factor: 2.935

Review 10.  Methodological assessment of HCC literature.

Authors:  G Daniele; N Costa; V Lorusso; J Costa-Maia; I Pache; M Pirisi
Journal:  Ann Oncol       Date:  2013-04       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.